Mehrad Adibi

ORCID: 0000-0002-9351-5913
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Renal cell carcinoma treatment
  • Urinary and Genital Oncology Studies
  • Renal and related cancers
  • Urological Disorders and Treatments
  • Testicular diseases and treatments
  • Prostate Cancer Treatment and Research
  • Genital Health and Disease
  • Urologic and reproductive health conditions
  • Multiple and Secondary Primary Cancers
  • Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Sexual Differentiation and Disorders
  • Radiopharmaceutical Chemistry and Applications
  • Glioma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Urinary Tract Infections Management
  • Esophageal Cancer Research and Treatment
  • Sexual function and dysfunction studies
  • Neuroblastoma Research and Treatments
  • Advanced Neural Network Applications
  • Genetic and Kidney Cyst Diseases
  • Advanced Image and Video Retrieval Techniques
  • Genetic factors in colorectal cancer
  • Cancer, Lipids, and Metabolism

The University of Texas MD Anderson Cancer Center
2014-2025

The University of Texas Southwestern Medical Center
2007-2016

Rogers (United States)
2016

Southwestern Medical Center
2011-2012

We examined the effect of radical nephrectomy, partial nephrectomy and radio frequency ablation on renal function in patients with stage T1a masses.A total 242 consecutive from July 1995 to March 2005 undergoing primary treatment for unilateral masses smaller than 4 cm a normal contralateral kidney were identified. Renal was calculated using modified Modification Diet Disease equation. The rate decrease glomerular filtration below 60 ml per minute 1.73 m2 compared among 3 modalities.A 86, 85...

10.1016/j.juro.2007.08.156 article EN The Journal of Urology 2007-12-05

We evaluated the incidence of infectious complications requiring hospitalization after transrectal ultrasound guided prostate biopsy, comparing an augmented regimen antibiotic prophylaxis to standard regimen, and established cost-effectiveness at our center.Our consisted 3 days ciprofloxacin or Bactrim™ DS in perioperative period. An increase hospital admissions related infection biopsy from January 2010 through December led us initiate Bactrim addition 1 dose intramuscular gentamicin before...

10.1016/j.juro.2012.08.194 article EN The Journal of Urology 2012-10-08

We examined the incidence, characteristics and treatment of patients with tumor bed recurrence after partial nephrectomy.We retrospectively reviewed charts 2,256 sporadic small renal masses treated nephrectomy between 2000 2014. Local was strictly defined as detection a new enhancing lesion 1) specifically in surgical defect or 2) same region (eg lower pole) site. To determine differences multiple 44 (1.9%) local were compared to 163 randomly selected who underwent no recurrence.Patients...

10.1016/j.juro.2017.09.072 article EN The Journal of Urology 2017-09-21

Objective: To evaluate temporal trends in clinicopathological features and oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Methods: Utilizing a multi‐institutional database of patients treated with between 1983 2007, we compared survival over the past three decades using following cohorts: group 1 comprised before 1990s ( n = 106), 2 from 1990 to1999 655), 3 2000 to 2007 701). Survival rates were Kaplan−Meier analysis. Results: The study included...

10.1111/j.1442-2042.2012.03110.x article EN International Journal of Urology 2012-08-12

Isolated local retroperitoneal recurrence after radical nephrectomy for renal cell carcinoma poses a therapeutic challenge. We investigated outcomes in patients with localized treated surgical resection.

10.1016/j.juro.2015.02.2943 article EN The Journal of Urology 2015-03-07

Study Type – Diagnostic (cost effectiveness analysis) Level of Evidence 3a What's known on the subject? and What does study add? Multiple studies have shown an increase in hospital admission rates due to infectious complications after transrectal ultrasonography (TRUS)‐guided prostate biopsy (TRUSBx), mostly related a rise prevalence fluoroquinolone‐resistant organisms. As result, multiple series advocated use more intensive prophylactic antibiotic regimens augment effect widely used...

10.1111/j.1464-410x.2011.10768.x article EN BJU International 2011-11-24

We present patient reported outcomes from our 5-year experience using penile plication to correct a wide variety of Peyronie disease malformations.We reviewed the records all men who underwent for disease, as performed by one us (AFM). All patients were treated with tunical without degloving via 2 cm longitudinal incision regardless curvature severity or erectile function. A concomitant inflatable prosthesis was placed in refractory dysfunction. questionnaire administered assess perception...

10.1016/j.juro.2012.09.085 article EN The Journal of Urology 2012-09-24

Background Testicular germ cell tumors (T-GCTs) occur from infancy to adulthood, and are the most common solid tumor in adolescent young adult males. Traditionally, pediatric T-GCTs were perceived as more indolent than T-GCTs. However, there few studies comparing these groups none that specifically evaluate adolescents. Methods An institutional database of T-GCT patients was reviewed categorized into Pediatric, aged 0–12 years, Adolescent, 13–19 Adult, older 20 cohorts. Demographics,...

10.1002/pbc.24773 article EN Pediatric Blood & Cancer 2013-09-17

630 Background: Adenocarcinomas of the urinary tract, including urachal (UA) and non-urachal (NUA) subtypes, are rare tumors. Triplet regimens combining gemcitabine, a taxane or 5-fluorouracil (5-FU)/leucovorin (L), cisplatin (P), have been developed. Methods: We retrospectively reviewed records patients receiving frontline (1L)GemFLP (Gemcitabine 200 mg/m 2 IV on days 1 5; 5-FU 1, 2, 3, 4, L 10mg/m P 20mg/m 5) in advanced UA NUA at MDACC between 2003 2023. Advanced disease is defined as...

10.1200/jco.2024.42.4_suppl.630 article EN Journal of Clinical Oncology 2024-01-29

We initiated a biomarker-informed preoperative study of infigratinib, fibroblast growth factor receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), population high unmet needs and tumor frequency FGFR3 alterations.

10.1097/ju.0000000000003928 article EN The Journal of Urology 2024-04-04

Endoscopic management (EM) is an increasingly accepted option for upper tract urothelial carcinoma (UTUC). Feasibility can be dependent on a variety of variables. The objective this study was to identify anatomic and phenotypic tumor characteristics that affect EM, using structured expert forecasting, develop obtain consensus assessment score, perform initial validation the score in retrospective database. We used modified Delphi method elicit opinions, scale, gain consensus. Two survey...

10.1097/ju.0000000000004383 article EN The Journal of Urology 2025-03-07

Management of metastatic renal cell carcinoma with sarcomatoid dedifferentiation remains a therapeutic challenge no standard treatment strategies. We evaluated whether metastasectomy has any survival benefit in patients treated radical nephrectomy.From an institutional database 273 nephrectomy we matched 80 synchronous and asynchronous metastases for age, ECOG (Eastern Cooperative Oncology Group) performance status, histology lymph node status. Matched pairs were then retained only if who...

10.1016/j.juro.2016.03.144 article EN The Journal of Urology 2016-03-30
Coming Soon ...